الفهرس 
Reperfusion strategy for acute ST elevation myocardial infarctionOnly 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Reperfusion strategies in the early phase of treatment of acute myocardial infarction aim to rapidly normalize and maintain tissue perfusion. Primary PCI is the best current line of treatment.
It has well demonstrated benefits, saving lives and reducing left ventricular damage. The mega-trials have sent a clear message that the greatest benefits are seen with patients who are treated early.
Assessment of myocardial reperfusion & successful flow restoration depended on Angiographic criteria, clinical parameters, biochemical tests, electrocardiography, echocardiography as well as clinical follow up of MACCE.
Primary PCI is the preferred and proper line of treatment of STEMI patients because of the better clinical outcomes and the fewer side effects compared to thrombolytics.
Many new factors used to improve clinical outcome of primry PCI such as glycoprotein IIb/IIIa inhibitors.
The purpose of this study was to investigate the benefits of glycoprotein IIb/IIIa inhibitor (Eptifibatide) in patients with acute STEMI and treated with primary PCI.
In this study we included 40 patients presenting to the emergency department with acute STEMI for the first time who were eligible for primary percutaneous coronary intervention and we divided them randomsily to two groups, first group (A) receives I.V Eptifibatide and second groups didnot receive Eptifibatide (B).
All patients were subjected to a history taking and physical examination, ECG, routine lab tests including cardiac enzymes & Echocardiography.
Then we follow the angiographic and clinical condition of both groups in hospital and for two weeks after regarding primary points of TIMI flow, MBG and echocardiography and secondary points of death, reinfarction, TVR, stroke and bleeding complications.
We noticed that group (A) have improved primry points of TIMI flow and MBG even though before and after PCI and stent implantation.
Also we noticed that secondary end points in 15 days are improved in group (A) regarding death,TVR, stroke however bleeding risk was higher in group (A) patients and was mainly minor bleeding.